Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs.

Parmar JR, Forrest BD, Freeman RA.

Res Social Adm Pharm. 2016 Jul-Aug;12(4):638-54. doi: 10.1016/j.sapharm.2015.09.002. Epub 2015 Sep 16. Review.

PMID:
26443472
2.

Reason for Lawsuit in Spinal Cord Injury Affects Final Outcome.

Quigley RS, Akpolat YT, Forrest BD, Wongworawat MD, Cheng WK.

Spine (Phila Pa 1976). 2015 Jun 1;40(11):851-5. doi: 10.1097/BRS.0000000000000878.

PMID:
25768691
3.

A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older.

Forrest BD, Steele AD, Hiemstra L, Rappaport R, Ambrose CS, Gruber WC.

Vaccine. 2011 May 9;29(20):3633-9. doi: 10.1016/j.vaccine.2011.03.029. Epub 2011 Apr 5.

PMID:
21440036
4.

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.

Lum LC, Borja-Tabora CF, Breiman RF, Vesikari T, Sablan BP, Chay OM, Tantracheewathorn T, Schmitt HJ, Lau YL, Bowonkiratikachorn P, Tam JS, Lee BW, Tan KK, Pejcz J, Cha S, Gutierrez-Brito M, Kaltenis P, Vertruyen A, Czajka H, Bojarskas J, Brooks WA, Cheng SM, Rappaport R, Baker S, Gruber WC, Forrest BD.

Vaccine. 2010 Feb 10;28(6):1566-74. doi: 10.1016/j.vaccine.2009.11.054. Epub 2009 Dec 8.

PMID:
20003918
5.

Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older.

De Villiers PJ, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, Gruber WC, Forrest BD; LAIV Elderly Study Trial Network.

Vaccine. 2009 Dec 10;28(1):228-34. doi: 10.1016/j.vaccine.2009.09.092. Epub 2009 Sep 29.

PMID:
19796721
6.

A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children.

Breiman RF, Brooks WA, Goswami D, Lagos R, Borja-Tabora C, Lanata CF, Londoño JA, Lum LC, Rappaport R, Razmpour A, Walker RE, Gruber WC, Forrest BD.

Vaccine. 2009 Sep 4;27(40):5472-9. doi: 10.1016/j.vaccine.2009.07.002. Epub 2009 Jul 17.

PMID:
19616493
7.

Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.

Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD; D153-P504 LAIV Study Group.

Pediatr Infect Dis J. 2009 May;28(5):365-71. doi: 10.1097/INF.0b013e31819219b8.

PMID:
19395948
8.

Apnea and its possible relationship to immunization in ex-premature infants.

Cooper PA, Madhi SA, Huebner RE, Mbelle N, Karim SS, Kleinschmidt I, Forrest BD, Klugman KP.

Vaccine. 2008 Jun 25;26(27-28):3410-3. doi: 10.1016/j.vaccine.2008.04.037. Epub 2008 May 5.

PMID:
18490084
9.

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.

Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC.

Clin Vaccine Immunol. 2008 Jul;15(7):1042-53. doi: 10.1128/CVI.00397-07. Epub 2008 Apr 30.

10.

Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.

Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD.

Pediatrics. 2008 Mar;121(3):e568-73. doi: 10.1542/peds.2007-1405. Epub 2008 Feb 25.

PMID:
18299305
11.

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.

Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD; Pan-Asian CAIV-T Pediatric Efficacy Trial Network.

Pediatr Infect Dis J. 2007 Jul;26(7):619-28.

PMID:
17596805
12.

Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care.

Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, Skinner J, Saville MK, Gruber WC, Forrest BD; CAIV-T Pediatric Day Care Clinical Trial Network.

Pediatrics. 2006 Dec;118(6):2298-312.

PMID:
17142512
13.

Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.

Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD; CAIV-T Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):870-9.

PMID:
17006279
14.

Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.

Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ.

J Infect Dis. 2006 Aug 1;194(3):370-6. Epub 2006 Jun 23.

PMID:
16826486
15.

Neonatal administration of rhesus rotavirus tetravalent vaccine.

Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ.

Pediatr Infect Dis J. 2006 Feb;25(2):118-22.

PMID:
16462287
16.

Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain.

Mendelman PM, Rappaport R, Cho I, Block S, Gruber W, August M, Dawson D, Cordova J, Kemble G, Mahmood K, Palladino G, Lee MS, Razmpour A, Stoddard J, Forrest BD.

Pediatr Infect Dis J. 2004 Nov;23(11):1053-5.

PMID:
15545863
17.

International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.

Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, Cheng H, Li M, Wang CY, Koff WC.

Asian Pac J Allergy Immunol. 1997 Jun;15(2):105-13.

PMID:
9346275
18.

International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand.

Phanuphak P, Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S, Leesavan A, Forrest BD, Hanson CV, Li M, Wang CY, Koff WC.

Asian Pac J Allergy Immunol. 1997 Mar;15(1):41-8.

PMID:
9251847
19.

Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.

Kelleher AD, Emery S, Cunningham P, Duncombe C, Carr A, Golding H, Forde S, Hudson J, Roggensack M, Forrest BD, Cooper DA.

AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):29-32.

PMID:
8989424
20.

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine.

Leach A, Twumasi PA, Kumah S, Banya WS, Jaffar S, Forrest BD, Granoff DM, LiButti DE, Carlone GM, Pais LB, Broome CV, Greenwood BM.

J Infect Dis. 1997 Jan;175(1):200-4.

PMID:
8985221
21.

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE.

J Infect Dis. 1996 Feb;173(2):330-9.

PMID:
8568293
22.

Impairment of immunogenicity of Salmonella typhi Ty21a due to pre-existing cross-reacting intestinal antibodies.

Forrest BD.

Adv Exp Med Biol. 1995;371B:1649-52. No abstract available.

PMID:
7502875
23.

Diarrhoeal disease: current concepts and future challenges. Diarrhoeal disease and vaccine development.

Forrest BD.

Trans R Soc Trop Med Hyg. 1993 Dec;87 Suppl 3:39-41. Review.

PMID:
8108849
25.

Mucosal approaches to HIV vaccine development.

Forrest BD.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1523-5. Review. No abstract available.

PMID:
1466996
26.

Impairment of immunogenicity of Salmonella typhi Ty21a due to preexisting cross-reacting intestinal antibodies.

Forrest BD.

J Infect Dis. 1992 Jul;166(1):210-12. No abstract available.

PMID:
1607701
28.

Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a.

Forrest BD, LaBrooy JT, Dearlove CE, Shearman DJ.

Infect Immun. 1992 Feb;60(2):465-71.

29.

The antibody response to an oral Ty21a-based typhoid-cholera hybrid is unaffected by prior oral vaccination with Ty21a.

Dearlove CE, Forrest BD, van den Bosch L, La Brooy JT.

J Infect Dis. 1992 Jan;165(1):182-3. No abstract available.

PMID:
1727891
30.
31.

The ethics of placebos in AIDS drug trials.

Porter JD, Forrest BD, Kennedy AR.

HEC Forum. 1992;4(3):155-62. Review. No abstract available.

PMID:
10120020
32.
33.

Women, HIV, and mucosal immunity.

Forrest BD.

Lancet. 1991 Apr 6;337(8745):835-6. Review. No abstract available.

PMID:
1672924
34.

Specific immune response in the human respiratory tract following oral immunization with live typhoid vaccine.

Forrest BD, LaBrooy JT, Robinson P, Dearlove CE, Shearman DJ.

Infect Immun. 1991 Mar;59(3):1206-9.

35.

The human humoral immune response to Salmonella typhi Ty21a.

Forrest BD, LaBrooy JT, Beyer L, Dearlove CE, Shearman DJ.

J Infect Dis. 1991 Feb;163(2):336-45.

PMID:
1988518
36.

Specific immune response in humans following rectal delivery of live typhoid vaccine.

Forrest BD, Shearman DJ, LaBrooy JT.

Vaccine. 1990 Jun;8(3):209-12.

PMID:
2363299
37.

Lymphocyte activation as measured by interleukin-2 receptor expression to gluten fraction 111 in coeliac disease.

Penttila IA, Gibson CE, Forrest BD, Cummins AG, LaBrooy JT.

Immunol Cell Biol. 1990 Jun;68 ( Pt 3):155-60.

PMID:
2228030
38.

Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans.

Morris JG Jr, Takeda T, Tall BD, Losonsky GA, Bhattacharya SK, Forrest BD, Kay BA, Nishibuchi M.

J Clin Invest. 1990 Mar;85(3):697-705.

39.

The serum polymeric IgA antibody response to typhoid vaccination; its relationship to the intestinal IgA response.

Bartholomeusz RC, Forrest BD, Labrooy JT, Ey PL, Pyle D, Shearman DJ, Rowley D.

Immunology. 1990 Feb;69(2):190-4.

40.

Immunogenicity of a candidate live oral typhoid/cholera hybrid vaccine in humans.

Forrest BD, LaBrooy JT, Attridge SR, Boehm G, Beyer L, Morona R, Shearman DJ, Rowley D.

J Infect Dis. 1989 Jan;159(1):145-6. No abstract available.

PMID:
2909633
41.

The development of a bivalent vaccine against diarrhoeal disease.

Forrest BD.

Southeast Asian J Trop Med Public Health. 1988 Sep;19(3):449-57. Review.

PMID:
2464195
42.

Supplemental Content

Loading ...
Support Center